These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1837978)

  • 1. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia.
    Herting RL
    Ann N Y Acad Sci; 1991; 640():237-40. PubMed ID: 1837978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
    Dysken MW; Mendels J; LeWitt P; Reisberg B; Pomara N; Wood J; Skare S; Fakouhi JD; Herting RL
    J Am Geriatr Soc; 1992 May; 40(5):503-6. PubMed ID: 1634705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milacemide treatment in mice enhances acquisition of a Morris-type water maze task.
    Finkelstein JE; Hengemihle JM; Ingram DK; Petri HL
    Pharmacol Biochem Behav; 1994 Nov; 49(3):707-10. PubMed ID: 7862727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type.
    Cutler NR; Fakouhi TD; Smith WT; Hendrie HC; Matsuo F; Sramek JJ; Herting RL
    J Geriatr Psychiatry Neurol; 1993; 6(2):115-9. PubMed ID: 8512628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic therapy of Huntington's chorea.
    Giuffra ME; Mouradian MM; Chase TN
    Clin Neuropharmacol; 1992 Apr; 15(2):148-51. PubMed ID: 1350513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Milacemide therapy for Parkinson's disease.
    Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An NMDA intervention strategy in schizophrenia with "low-dose" milacemide.
    Rosse RB; Schwartz BL; Davis RE; Deutsch SI
    Clin Neuropharmacol; 1991 Jun; 14(3):268-72. PubMed ID: 1829980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milacemide enhances memory storage and alleviates spontaneous forgetting in mice.
    Quartermain D; Nuygen T; Sheu J; Herting RL
    Pharmacol Biochem Behav; 1991 May; 39(1):31-5. PubMed ID: 1833781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells.
    Godfraind JM
    Br J Pharmacol; 1990 May; 100(1):119-25. PubMed ID: 2196964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New therapeutic options in Alzheimer's disease].
    García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
    Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of milacemide, a glycine prodrug, on ethanol's antiseizure efficacy.
    Deutsch SI; Norris DO; O'Connor DA; Novitzki MR; Lukacs LG; Mastropaolo J
    Pharmacol Biochem Behav; 1992 Feb; 41(2):263-6. PubMed ID: 1533463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycine-prodrug, milacemide, increases the seizure threshold due to hyperbaric oxygen; prevention by 1-deprenyl.
    Youdim MB; Kerem D; Duvdevani Y
    Eur J Pharmacol; 1988 Jun; 150(3):381-4. PubMed ID: 3138141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells.
    Yadid G; Zinder O; Youdim MB
    Br J Pharmacol; 1991 Nov; 104(3):760-4. PubMed ID: 1797336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?
    O'Brien EM; Tipton KF; Strolin Benedetti M; Bonsignori A; Marrari P; Dostert P
    Biochem Pharmacol; 1991 Jun; 41(11):1731-7. PubMed ID: 2043162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive effects of milacemide and methylphenidate in healthy young adults.
    Camp-Bruno JA; Herting RL
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):46-52. PubMed ID: 7862911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.
    Handelmann GE; Nevins ME; Mueller LL; Arnolde SM; Cordi AA
    Pharmacol Biochem Behav; 1989 Dec; 34(4):823-8. PubMed ID: 2516327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists.
    Maurice T; Lockhart BP; Su TP; Privat A
    Brain Res; 1996 Aug; 731(1-2):249-53. PubMed ID: 8883881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.
    Semba J; Curzon G; Patsalos PN
    Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d-Cycloserine enhances implicit memory in Alzheimer patients.
    Schwartz BL; Hashtroudi S; Herting RL; Schwartz P; Deutsch SI
    Neurology; 1996 Feb; 46(2):420-4. PubMed ID: 8614505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.